RNXT
RenovoRx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RNXT
Renovorx, Inc.
A clinical-stage biopharmaceutical company that developing local therapies for solid tumors
4546 El Camino Real, Suite B1, Los Altos, CA 94022
--
RenovoRx, Inc., was incorporated in Delaware on December 17, 2012. The Company is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for highly unmet medical needs with the goal of improving treatment outcomes for cancer patients undergoing treatment. The Company's proprietary Transarterial Microperfusion (TAMPT) treatment platform is designed to ensure precise treatment delivery to directly target the tumor while potentially minimizing the toxicity of the treatment relative to systemic (intravenous (referred to as "IV ") treatment).
Company Financials
EPS
RNXT has released its 2025 Q3 earnings. EPS was reported at -0.08, versus the expected -0.08, meeting expectations. The chart below visualizes how RNXT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RNXT has released its 2025 Q3 earnings report, with revenue of 266.00K, reflecting a YoY change of NaN%, and net profit of -2.91M, showing a YoY change of -17.85%. The Sankey diagram below clearly presents RNXT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
